Stifel Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $200
Portfolio Pulse from Benzinga Newsdesk
Stifel has initiated coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and a price target of $200.
May 31, 2024 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel has initiated coverage on Ascendis Pharma with a Buy rating and a price target of $200, indicating strong confidence in the company's future performance.
The initiation of coverage with a Buy rating and a high price target of $200 by a reputable analyst firm like Stifel is likely to boost investor confidence in Ascendis Pharma. This could lead to increased buying activity and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100